Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research note released on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

Shares of NASDAQ ONVO opened at $0.68 on Friday. Organovo has a 12-month low of $0.64 and a 12-month high of $2.05. The firm has a market capitalization of $9.74 million, a price-to-earnings ratio of -0.42 and a beta of 0.68. The firm has a 50 day moving average of $0.90 and a 200 day moving average of $0.99.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.